![Frontiers | Salvage Therapy With Low-Dose Ruxolitinib Leads to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients With cGVHD After Allogeneic Hematopoietic Stem Cell Transplantation Frontiers | Salvage Therapy With Low-Dose Ruxolitinib Leads to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients With cGVHD After Allogeneic Hematopoietic Stem Cell Transplantation](https://www.frontiersin.org/files/Articles/668825/fphar-12-668825-HTML/image_m/fphar-12-668825-g001.jpg)
Frontiers | Salvage Therapy With Low-Dose Ruxolitinib Leads to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients With cGVHD After Allogeneic Hematopoietic Stem Cell Transplantation
![The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant (STOP-BOS) trial | Bone Marrow Transplantation The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant (STOP-BOS) trial | Bone Marrow Transplantation](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41409-022-01716-4/MediaObjects/41409_2022_1716_Fig1_HTML.png)
The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant (STOP-BOS) trial | Bone Marrow Transplantation
![PDF) Bronchiolitis Obliterans Syndrome in Lung Transplant Recipients: Can Thin-Section CT Findings Predict Disease before Its Clinical Appearance? PDF) Bronchiolitis Obliterans Syndrome in Lung Transplant Recipients: Can Thin-Section CT Findings Predict Disease before Its Clinical Appearance?](https://i1.rgstatic.net/publication/8576657_Bronchiolitis_Obliterans_Syndrome_in_Lung_Transplant_Recipients_Can_Thin-Section_CT_Findings_Predict_Disease_before_Its_Clinical_Appearance/links/5643563f08aef646e6c69e40/largepreview.png)
PDF) Bronchiolitis Obliterans Syndrome in Lung Transplant Recipients: Can Thin-Section CT Findings Predict Disease before Its Clinical Appearance?
![PDF) Bimatoprost Ophthalmic Solution (BOS) 0.3 mg w/v for 1 Open Trial of Long-term Preventive Therapy of Migraine in 3 patients with Pathophysiologic Shift from Brain to Eye PDF) Bimatoprost Ophthalmic Solution (BOS) 0.3 mg w/v for 1 Open Trial of Long-term Preventive Therapy of Migraine in 3 patients with Pathophysiologic Shift from Brain to Eye](https://i1.rgstatic.net/publication/375689562_Bimatoprost_Ophthalmic_Solution_BOS_03_mg_wv_for_1_Open_Trial_of_Long-term_Preventive_Therapy_of_Migraine_in_3_patients_with_Pathophysiologic_Shift_from_Brain_to_Eye/links/6556219cce88b87031ed2b70/largepreview.png)
PDF) Bimatoprost Ophthalmic Solution (BOS) 0.3 mg w/v for 1 Open Trial of Long-term Preventive Therapy of Migraine in 3 patients with Pathophysiologic Shift from Brain to Eye
![Diagnostics | Free Full-Text | Lung Transplantation: CT Assessment of Chronic Lung Allograft Dysfunction (CLAD) Diagnostics | Free Full-Text | Lung Transplantation: CT Assessment of Chronic Lung Allograft Dysfunction (CLAD)](https://www.mdpi.com/diagnostics/diagnostics-11-00817/article_deploy/html/images/diagnostics-11-00817-g002.png)
Diagnostics | Free Full-Text | Lung Transplantation: CT Assessment of Chronic Lung Allograft Dysfunction (CLAD)
![Developing a novel inhaled therapeutic for the treatment of bronchiolitis obliterans syndrome - Research Outreach Developing a novel inhaled therapeutic for the treatment of bronchiolitis obliterans syndrome - Research Outreach](https://researchoutreach.org/wp-content/uploads/2019/08/BronchioleHiRes.jpg)
Developing a novel inhaled therapeutic for the treatment of bronchiolitis obliterans syndrome - Research Outreach
![Appendix I - Sample Agenda from BOS Family Assistance Training Workshop | Emergency Working Groups at Airports | The National Academies Press Appendix I - Sample Agenda from BOS Family Assistance Training Workshop | Emergency Working Groups at Airports | The National Academies Press](https://nap.nationalacademies.org/books/25572/gif/75.gif)